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Abstract
Background: Non-optic gliomas occur in 5% of children with NF1, but little is known about these tumours in
adults. We aimed to investigate progression, spontaneous regression and the natural history of non-optic gliomas
in adults and compare these findings to the results found in children.
Results: One thousand seven hundred twenty-two brain MRI scans of 562 unselected individuals with NF1 were
collected at the NF outpatient department of the University Hospital Hamburg-Eppendorf between 2003 and 2015.
The number of scans per patient ranged from one to 12; patients were followed for a median of 3.7 years. We
identified 24 patients (4.3%) with non-optic gliomas. Median age at first scan with glioma was 21.2 years, much
higher than in previous publications. Only seven of the 24 non-optic glioma patients were symptomatic. Five of 24
patients had multiple non-optic gliomas. Four individuals developed a new tumour, and 4 cases showed
progression. The risk of new tumour development was 0.19% (95% confidence interval 0.06% to 0.52%) per patient
year of follow-up for patients over 10 years. The rate of progressing non-optic gliomas per patient year of follow-up
in the first 5 years after tumour diagnosis was 4.7% (95% confidence interval 1.5% to 12%).
Conclusions: Non-optic gliomas are twice as common in an unselected cohort of NF1 patients as previously
reported. This is likely due to increased frequency of diagnosis of asymptomatic tumours when routine MRIs are
performed and a higher prevalence in older individuals.
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Background
Neurofibromatosis 1 (NF1) is an autosomal dominant
disorder with an estimated incidence of 1 in 3000 live
births [1]. It is caused by mutations in the NF1 gene, a
suppressor of the RAS kinase pathway. As a result of the
NF1 protein’s ubiquitous expression and important role
in cellular regulation, patients with mutations in the
NF1 gene develop e.g., neurofibromas and other neo-
plasms and pigmentary abnormalities of the skin [2].
Gliomas outside of the optic pathways are one of the
most common causes of death in NF1 patients [3, 4].
Non-optic gliomas in NF1 patients are usually located in
the brainstem or cerebellum and are almost exclusively
reported in children, although non-optic gliomas are
known to occur in adults with NF1 as well [5]. Approxi-
mately 5% of children with NF1 develop a non-optic gli-
oma, a prevalence more than 100 times greater than in
the general population [6]. Non-optic gliomas in NF1
patients are usually low-grade astrocytomas and often
have a more benign course than in people without NF1
[7–9]. Their natural history is only incompletely under-
stood [10]. The occurrence of non-optic gliomas has
been found to be associated with the presence of optic
gliomas in children with NF1 in some studies [11, 12].
MRI is commonly used to evaluate intracranial tu-
mours in clinical as well as research settings [13]. MRI
provides information on the presence, location, and size
of the tumour and is a crucial tool in routine clinical
care of gliomas in individuals with or without NF1.
In this study, we investigated the natural history,
progression, and regression of non-optic gliomas in an
unselected cohort of adults and children with NF1.
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Between 2003 and 2015, all patients with NF1 diagnosed
according to standard clinical criteria seen in the NF
outpatient department of the University Hospital
Hamburg–Eppendorf were offered brain MRIs [14]. Be-
cause patients were not selected for imaging on the basis
of clinical symptoms, they are representative of the NF1
population seen in the clinic.
The ethical committees of the Medical Chamber in
Hamburg and the Research Ethics Board of the Univer-
sity of British Columbia approved the study. Written
consent was obtained from all study participants before
study begin. All data were de-identified before analysis.
MRI imaging
Lesions that were hyperintense in T2 without mass effect
and enhancement were identified as unidentified bright
objects (UBO). In order to distinguish gliomas from
UBOs, we used the following criteria: location and size
of a lesion, the presence of mass effect, the lesion being
hyperintense in T2 and hypointense in T1, and evolution
over time.
Based on the 1722 German clinical MRI reports, a list
of patients was generated who had been diagnosed with
non-optic gliomas. All brain MRIs from these patients
were re-evaluated by two neuroradiologists in Canada
(M.M. and M.K.S.H.), and the presence of non-optic
gliomas in each individual patient was established by
consensus using the criteria described above.
In NF1 patients without anomalies on head MRI,
follow-up imaging was performed in 2-year intervals. In
patients with asymptomatic non-optic gliomas, imaging
was repeated after 1 year. In patients with clinically or
radiologically progressive non-optic gliomas, re-imaging
was performed at 6-month intervals. Treatment deci-
sions were based on location and severity of symptoms
in symptomatic patients, and based on location and rate
of tumour growth in asymptomatic patients. Surgical re-
section was the treatment of choice if it could be done
safely; if the tumour was unresectable, chemotherapy
was offered.
Tumour volume was calculated by using a box model.
New appearance of a glioma was defined when an indi-
vidual had a tumour on at least one MRI in an area that
was well imaged but no tumour was seen in at least one
previous scan. Progression of a non-optic glioma was de-
fined as an increase in volume of at least 30% per year.
Descriptive statistical analysis
Patients were divided into 10-year age groups and only
counted once per age group. Patients who were scanned
in more than one decade of life were counted once in
each age group in which a scan was performed. Patients
with more than one glioma present were counted only
once per age group. Ninety-five percent confidence
intervals of the percentages were calculated as ± 1.96
standard deviations of a Poisson distribution.
Tumour volume in younger patients was compared to
that in older patients with a Mann–Whitney U test.
Ninety-five percent confidence intervals for rates of newly
appearing tumours and progressing tumours were calcu-
lated using Wilson’s method with continuity correction.
Results were considered to be significant if p ≤ 0.05.
Results
Demographics
A total of 562 patients with NF1, 264 males and 298 fe-
males (1.0:1.1 ratio), were included in this study (see
Figs. 1a and 2). One thousand seven hundred twenty-two
MRI scans were performed, with a median of two scans
per person (range, 1 to 12 scans) and a median follow-up
time of 3.7 years (range, 0 to 13.0 years). At the time of
the MRI scan, their ages ranged from 0.4 to 72.8 years.
During the study period, 51 patients were lost to
follow-up and 24 died of reasons unrelated to non-optic
gliomas, equaling a dropout rate of 13.3%.
Number of patients with non-optic glioma by age group
A diagnosis of non-optic glioma was made on clinical
reading of the brain MRI images in 27 NF1 patients. In
24 of these cases, the study neuroradiologists (M.M. and
M.K.S.H.) were able to confirm the definite presence of
a non-optic glioma using the study criteria.
Thus, a total of 24 (4.3%) of the 562 NF1 patients were
diagnosed with non-optic glioma. The prevalence of
individuals diagnosed with non-optic glioma per 10-year
age group is shown in Fig. 1b. Follow-up of the 24 non-
optic glioma patients ranged between 0 years and
11.8 years, with a median of 5.0 years of follow-up and a
combined total of 134 years of follow-up.
Clinical description of gliomas
An overview of all non-optic glioma cases is provided in
Table 1. There were a total of 32 gliomas in 24 patients.
Nineteen patients had one glioma, two patients had two
non-optic gliomas, and three patients had three non-
optic gliomas. Only seven of the 24 non-optic tumour
patients were symptomatic. Individual tumour volumes
ranged from 0.04 cm3 to 98.4 cm3, with a median volume
of 1.6 cm3.
Twenty-five of 32 tumours enhanced after administra-
tion of gadolinium. Eight tumours showed avid enhance-
ment, four tumours showed diffuse enhancement, and
enhancement was patchy or peripheral in 13 tumours.
Enhancement increased in three tumours and decreased
in another three tumours. These changes were not
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associated with alterations in clinical status or other
radiological features.
Nine patients received treatment for their gliomas
(Table 1): eight patients underwent surgery and one
patient received vincristine and carboplatin following a
biopsy. None of these nine patients had recurrence or fur-
ther growth of their non-optic gliomas after treatment.
Histology was available on nine tumours. Eight tu-
mours were pilocytic astrocytomas (PAs) (WHO Grade
1) and one was a dysembryoplastic neuroepithelial
tumour (DNET). DNETs are of glioneuronal origin and
are classified as WHO Grade 1. There were no higher-
grade tumours.
Three patients with non-optic gliomas had concurrent
optic gliomas (Patients 9, 11 and 19 in Table 1). There
was no significant association between the presence of
non-optic gliomas and optic gliomas (χ2 = 0.31, p = 0.57).
Newly diagnosed non-optic gliomas
There were four individuals with newly-appearing gliomas
(see Fig. 2) (Patients 9c, 11, 12b, and 19 in Table 1). Since
glioma prevalence is stable in patients over 10 years, we
determined the rate of new tumours appearing during
2111 years of follow-up of patients age 10 and older. Four
new tumours appeared, resulting in a rate of 0.19% (95%
confidence interval 0.06% to 0.52%) of new non-optic gli-
oma development per patient year of follow-up. There
were no newly-appearing non-optic gliomas in the
266 years of follow-up of children younger than 10 years.
Progressing gliomas
We identified glioma progression in four individuals
(Fig. 3) (Patients 10, 19, 23, and 24b in Table 1). The rate
of progressing non-optic gliomas per patient year of
follow-up in the first 5 years after tumour diagnosis was
Fig. 1 Demographics and percentage of NF1 patients affected by non-optic glioma per age group. a Number of male and female NF1 patients
per age group. Each person is counted once per age group, regardless of number of scans in that age group. Individuals may appear in more
than one age group if scanned in more than one age range. b The overall prevalence of non-optic glioma appears stable in adulthood. Each
person is counted once per age group, regardless of number of scans in that age group. Individuals may appear in more than one age group if
scanned in more than one age range. Error bars are 1.96 standard deviations of a Poisson distribution
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4.7% (95% confidence interval 1.5% to 12%). No progres-
sion events were observed in the 48.1 patient years of
follow-up that were more than 5 years after diagnosis.
Tumours in four of 21 non-optic glioma patients pro-
gressed (three patients did not have follow-up after
tumour diagnosis).
Regressing gliomas
There were no spontaneously regressing gliomas in our
study.
Correlation of presence non-optic gliomas with presence
of UBOs
A study by Griffiths et al. suggested that gliomas might
arise from unidentified bright objects (UBOs) in children
with NF1 [15]. We focused on the 4 patients with
newly-appearing tumours (Patients 9, 11, 12, and 19 in
Table 1) and assessed if they had UBOs in the location
where the glioma later appeared.
None of the four non-optic glioma patients with
newly-appearing gliomas had UBOs at the location of
their tumour before it appeared.
Discussion
This study comprises the world’s largest collection of
unselected brain MRIs of NF1 patients reported to date.
Twenty-four (4.3%) of 562 patients were diagnosed with
non-optic gliomas. This overall prevalence is 1.5× to 3×
higher than in previously published prospective studies
(Table 2) [11, 16–21].
This difference can be explained in part by the fact
that the majority of non-optic glioma patients are
asymptomatic (seven of our 24 glioma patients were
symptomatic) and could only be detected by offering
MRIs to all NF1 patients, as was done in our study.
The median age at first scan in this study is 21.2 years –
much higher than the usual age at diagnosis of non-optic
gliomas in NF1 patients (Table 2).
Fig. 2 Newly-appearing glioma in the left cerebral peduncle in Patient 19. a There is no visible glioma on the patient’s first scan. b 4 years later,
an enhancing glioma has appeared in the left cerebral peduncle measuring 0.5 cm3. c 5 years after the initial glioma-free scan, the glioma has
increased to a volume of 0.8 cm3. d 7 years after the initial scan, the glioma measured 1.3 cm3. All images shown are FLAIR sequences. The
patient remained asymptomatic during follow-up and also has an optic glioma (not visible in these images)
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Since our study uses age at first scan with glioma and not
age at glioma diagnosis to infer prevalence, cases in younger
age groups might be underrepresented. Additionally, the
majority of adult NF1 patients with gliomas are asymptom-
atic and some symptoms of brain tumours are also
common in NF1 patients without brain tumours (e.g.,
Table 1 Clinical features of non-optic gliomas in NF1 patients
Patient number Sex Age at first scan with
glioma (in years)
Symptoms Histology Location Status Treatment
1 M 20.9 Headache PA Grade 1 Frontal Decreased size Surgery
2 F 41.6 No Temporal Decreased size Chemotherapy
(breast cancer)
3 F 48.6 No Brainstem Stable
4 F 50.8 No Temporal No follow up
5 F 23.4 Seizures Brainstem Stable
6 F 10.0 Seizures, headache Cerebellum Stable
7 M 31.3 No Brainstem Stable
8 M 13.1 No Frontal Stable
9ab M 44.6 Ataxia Cerebellum Stable
9bb M 44.6 Ataxia Cerebellum Stable
9cab M 50.5 Ataxia PA Grade 1 Cerebellum Increased, then
decreased size
Surgery




11ab F 34.9 No Brainstem No follow up
12a F 16.4 No PA Grade 1 Corpus Callosum Increased enhancement Incomplete
resection before
study begin
12ba F 25.3 No Brainstem Stable
13 F 38.5 No Cerebellum Stable
14 M 17.2 Seizures, headache PA Grade 1 Cerebellum Stable Surgery
15 M 21.3 No PA Grade 1 Corpus Callosum Decreased size &
enhancement
Surgery
16 M 42.5 No Temporal Stable
17 M 42.7 Seizures DNET Cerebellum Stable Incomplete
resection before
study begin
18a F 14.8 No PA Grade 1 Corpus Callosum No follow up Surgery
18b F 14.8 No Thalamus No follow up
19ab F 18.3 No Brainstem Increased in size
20 F 16.0 No Internal capsule Decreased enhancement
21 F 39.8 No Cerebellum Stable
22a F 10.9 No Cerebellum Decreased enhancement
22b F 10.9 No Cerebellum Increased, then
decreased in size
22c F 10.9 No Cerebellum Stable
23 M 17.4 No Brainstem Increased size &
enhancement
24a M 18.1 Double vision, nystagmus PA Grade 1 Brainstem Decreased size Surgery
24b M 18.1 Double vision, nystagmus Corpus Callosum Increased size
24c M 18.1 Double vision, nystagmus Cerebellum Stable
Abbreviations: PA pilocytic astrocytoma, M male, F female, DNET dysembryoplastic neuroepithelial tumour
adenotes patients with newly-appearing tumours
bdenotes patients with concurrent optic gliomas
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headache). Even though it is known that NF1 patients have
a lifelong elevated risk for tumour development, brain
MRIs are not currently recommended for tumour surveil-
lance in NF1 patients of any age as part of regular clinical
care [7, 22].
The largest group of adult NF1 patients with non-
optic gliomas was described by Gutmann et al. [5] Only
three of 15 tumours for which histology was available
were Grade 1, compared to nine of nine in our study.
This may be explained by Gutmann et al. only reporting
symptomatic tumours, which are more likely to be high-
grade than asymptomatic tumours. Other authors
reported three adult cases, two of which were asymp-
tomatic [23].
Intracranial gliomas in NF1 patients are usually associ-
ated with a better outcome than those diagnosed in the
non-NF1 setting [24, 25]. Most of the tumours biopsied
in this study were PAs – the most common histological
type of intracranial tumour [26]. The 5-year survival rate
of NF1 patients with PA was estimated to be 85% [25].
However, this was calculated for patients who underwent
surgery for their gliomas, so the true 5-year survival rate
is likely much higher than 85%. In further support of
this, none of our brain tumour patients with or without
biopsy-proven PA died during a cumulative 134 patient
years of follow-up.
While malignant transformation of low-grade non-
optic gliomas has been described in NF1 patients [27, 28],
this appears to be infrequent [29]. We did not see any
cases of malignant transformation in this study.
The majority of non-optic gliomas in children with
NF1 reported in the literature have been located in the
posterior fossa [9, 30]. We observed the same thing in
our study. We also found that the majority of non-optic
gliomas in adults with NF1 were located in the posterior
fossa. Previous reports suggested that these tumours
usually occur in other locations in adults [5], but previ-
ous studies of non-optic gliomas in adults with NF1 have
been small and focused on symptomatic patients. Most
of the patients in our study were asymptomatic.
There were five patients with multiple non-optic gli-
omas. These lesions could either be multiple primary
tumours, or multifocal gliomas. Gliomas in NF1 patients
were shown to be multifocal [25]; however, it is impos-
sible to distinguish between multifocal and multiple
primary tumours without performing molecular ana-
lyses. The chance of having 1 non-optic glioma accord-
ing to our results is 4.3%; therefore we expected to find
one individual with two primary non-optic gliomas and
0 individuals with three primary non-optic gliomas by
chance in a series of this size. We found two patients
with two gliomas and three patients with three gliomas
each. Even though these numbers are small, they support
the possibility that a patient is more likely to develop
additional non-optic tumours if he or she has already
developed one. There is a correlation between the occur-
rence of optic and non-optic gliomas in people with NF1
[11]; however, a correlation between the development of
non-optic gliomas has not previously been suggested.
There are case reports of NF1 patients with more than
one non-optic glioma, and all of these patients were
Fig. 3 Progressing glioma in Patient 9. a First scan with glioma present
in the left cerebral peduncle and left thalamus on FLAIR sequence. b
Another scan performed 2 years after the previous one (again FLAIR
sequence). The glioma has drastically increased in size and was treated
with chemotherapy 1 month after this image was taken
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symptomatic [31]. Only two of the five patients in our
study showed symptoms, so NF1 patients can have mul-
tiple brain tumours and remain asymptomatic. A publi-
cation assessing prognostic factors for NF1 patients with
brain tumours found that having multiple tumours is
not a risk factor for death [32]; however, it did not
distinguish between optic and non-optic tumours.
Tumours in adults with NF1 are said to be higher-grade
and carry a worse prognosis than those in children with
NF1 [32, 33]; however, we did not find any higher-grade
tumours in adults. This difference probably reflects the
fact that adults were only included in previous studies if
they had aggressive tumours, whereas our study included
individuals independent of the presence of symptoms.
In order to compare tumour volumes of younger and
older non-optic glioma patients, we separated the cohort
into two groups, using the median age at diagnosis
(21.2 years) as cut-off. Tumours in patients diagnosed
before 21.2 years had a significantly greater volume than
those in patients diagnosed later (Mann–Whitney U test,
p = 0.02). This is counterintuitive if most tumours in
adults arose in childhood or adolescence and tumours
only grow in young patients. However, a similar observa-
tion has been made for plexiform neurofibromas in
people with NF1 – the most rapid growth occurs during
childhood but the tumour volume is inversely correlated
with age [34]. In addition to having larger tumours,
seven of the nine individuals requiring treatment of their
non-optic tumour were diagnosed before 21.2 years of
age. One possible explanation for the differences in
tumour volume between children and adults is that large
tumours in childhood require treatment or have fatal
consequences, thus only leaving patients with small in-
dolent tumours to be identified later.
One of the limitations of our study is that patients re-
ferred to the NF clinic are probably not representative of
the NF1 patient population as a whole. Patients with
milder manifestations may be less likely to be referred
than those more severely affected. In addition, patients
with e.g., brain tumours are more likely to get follow-up
scans than tumour-free patients. Another limitation is that
even though all parents were offered brain MRIs for their
children, parents of asymptomatic children might be more
likely to refuse MRI, which requires sedation, than parents
of symptomatic children. Therefore, this study is probably
biased towards patients with a more severe phenotype. It
is important to note that there were patients seen in the
NF outpatient department who had higher-grade tumours
but were not included in this study.
There is currently no recommended head MRI screen-
ing protocol for patients with NF1, whether or not they
have non-optic gliomas. We screen NF1 patients without
non-optic gliomas every 2 years, patients with asymp-
tomatic gliomas every 12 months, and patients with
symptomatic gliomas every 6 months. A much larger
longitudinal cohort study would be necessary to deter-
mine if this is the optimal approach.
Non-optic gliomas may occur in children as well as
adults with NF1, and these tumours should be consid-
ered as a possible cause of neurological symptoms that
develop in NF1 patients of any age.
Conclusion
We determined the rate of appearance, progression and
spontaneous regression in an unbiased NF1 cohort. This
is the largest prospective study of unselected brain MRIs
ever published and also the first study to compare glioma
frequency and natural history in an unselected cohort with
an age range this wide. Our data should be considered
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Rates of tumours How were tumour
patients identified?
Cnossen et al. [16] P 150 0–18 Unknown 4 2.70% Symptomatic
patients
Zöller et al. [17] P 70 20–81 Unknown 1 1.43% Cross-referencing
with cancer registry
Friedman and Birch [11] R 684 0–73 <6 years 25 3.65% MRI/CT*
McGaughran et al. [18] R 523 0–74 Unknown 12 2.29% Symptomatic patients
Menor et al. [19] R 72 0.8–14 Unknown 8 11% MRI*
Seminog and Goldacre [20] R 6739 0–80+ Unknown 322 4.78% Hospital records
Varan et al. [21] R 473 0–33 8 years 11 2.32% Symptomatic patients
*denotes studies for which convenience MRI/CT images were used
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